Physician profile
John H Harney
NPI 1528029584
$10,987.96
in general payments reported to CMS, 2019-2025
61 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,335 · 2020: $1,754 · 2021: $3,734 · 2022: $2,166.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,129.58 | 2019-2022 | |
| Biogen, INC. | $765.45 | 2019-2022 | |
| Amgen INC. | $648.82 | 2019-2022 | |
| Abbvie INC. | $645.29 | 2021-2022 | |
| Emd Serono, INC. | $563.88 | 2019-2022 | |
| Allergan, INC. | $545.51 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $537.12 | 2019-2021 | |
| Genzyme Corporation | $491.30 | 2019-2021 | |
| Ucb, INC. | $402.68 | 2019-2022 | |
| Genentech USA, INC. | $402.17 | 2019-2022 | |
| Acorda Therapeutics, INC | $393.73 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $347.33 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $316.77 | 2019-2021 | |
| Eisai INC. | $308.14 | 2019-2022 | |
| Grifols USA, LLC | $212.45 | 2019 |
Show all 61 companies
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Harney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.